Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CCCC NASDAQ:PBYI NASDAQ:SRZN NASDAQ:UPXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCCCC4 Therapeutics$3.63-1.4%$2.87$1.21▼$3.95$405.47M2.772.85 million shs2.82 million shsPBYIPuma Biotechnology$7.19+0.3%$6.86$2.85▼$7.90$364.95M1.24296,945 shs251,403 shsSRZNSurrozen$29.87-0.9%$28.76$5.90▼$35.00$349.94M0.59110,545 shs14,861 shsUPXIUpexi$1.52+9.4%$1.17$0.54▼$15.50$97.66M-0.323.47 million shs4.57 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCCCC4 Therapeutics-1.36%+21.81%+30.58%+92.06%+164.96%PBYIPuma Biotechnology+0.28%-0.96%-5.02%+5.43%+147.93%SRZNSurrozen-0.90%-2.86%-6.22%+22.02%+359.54%UPXIUpexi+9.35%+13.43%+26.67%+97.40%-84.46%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCCCC4 Therapeutics$3.63-1.4%$2.87$1.21▼$3.95$405.47M2.772.85 million shs2.82 million shsPBYIPuma Biotechnology$7.19+0.3%$6.86$2.85▼$7.90$364.95M1.24296,945 shs251,403 shsSRZNSurrozen$29.87-0.9%$28.76$5.90▼$35.00$349.94M0.59110,545 shs14,861 shsUPXIUpexi$1.52+9.4%$1.17$0.54▼$15.50$97.66M-0.323.47 million shs4.57 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCCCC4 Therapeutics-1.36%+21.81%+30.58%+92.06%+164.96%PBYIPuma Biotechnology+0.28%-0.96%-5.02%+5.43%+147.93%SRZNSurrozen-0.90%-2.86%-6.22%+22.02%+359.54%UPXIUpexi+9.35%+13.43%+26.67%+97.40%-84.46%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCCCCC4 Therapeutics 2.57Moderate Buy$7.75113.50% UpsidePBYIPuma Biotechnology 2.00HoldN/AN/ASRZNSurrozen 2.80Moderate Buy$42.0040.61% UpsideUPXIUpexi 2.67Moderate Buy$8.33448.25% UpsideCurrent Analyst Ratings BreakdownLatest UPXI, PBYI, SRZN, and CCCC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/11/2026PBYIPuma Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/11/2026UPXIUpexi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/7/2026SRZNSurrozen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$36.00 ➝ $44.004/21/2026PBYIPuma Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)4/21/2026SRZNSurrozen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026SRZNSurrozen TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy4/20/2026CCCCC4 Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/9/2026UPXIUpexi Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/24/2026SRZNSurrozen Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$40.003/24/2026SRZNSurrozen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$32.00 ➝ $36.002/26/2026CCCCC4 Therapeutics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$5.00 ➝ $7.00(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCCCCC4 Therapeutics$34.86M11.47N/AN/A$2.12 per share1.71PBYIPuma Biotechnology$228.40M1.60$0.84 per share8.59$2.52 per share2.85SRZNSurrozen$3.48M99.65N/AN/A($23.96) per share-1.25UPXIUpexi$15.81M6.75N/AN/A($0.74) per share-2.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCCCCC4 Therapeutics-$104.99M-$1.19N/AN/AN/A-297.76%-50.68%-33.22%N/APBYIPuma Biotechnology$31.11M$0.4814.9837.84N/A10.69%20.30%12.05%N/ASRZNSurrozen-$242.03M-$37.59N/AN/AN/A-4,810.50%-4,055.04%-154.08%N/AUPXIUpexi-$13.68M-$3.23N/AN/AN/A-874.00%-66.70%-19.56%N/ALatest UPXI, PBYI, SRZN, and CCCC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026CCCCC4 Therapeutics-$0.2506-$0.20+$0.0506-$0.20$4.42 million$6.15 million5/12/2026Q3 2026UPXIUpexi-$0.20-$1.67-$1.47-$1.67$2.90 million$1.05 million5/7/2026Q1 2026PBYIPuma Biotechnology-$0.13-$0.04+$0.09-$0.07$42.00 million$44.81 million5/6/2026Q1 2026SRZNSurrozen-$1.0920-$11.65-$10.5580-$11.65$4.00 million$5.00 million3/23/2026Q4 2025SRZNSurrozen-$1.2875-$7.59-$6.3025-$23.88$0.66 million$0.53 million2/26/2026Q4 2025CCCCC4 Therapeutics-$0.43-$0.18+$0.25-$0.18$4.48 million$11.02 million2/26/2026Q4 2025PBYIPuma Biotechnology$0.24$0.26+$0.02$0.26$68.60 million$75.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCCCCC4 TherapeuticsN/AN/AN/AN/AN/APBYIPuma BiotechnologyN/AN/AN/AN/AN/ASRZNSurrozenN/AN/AN/AN/AN/AUPXIUpexiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCCCCC4 TherapeuticsN/A9.007.81PBYIPuma BiotechnologyN/A2.381.93SRZNSurrozenN/A11.9111.91UPXIUpexi2.961.722.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCCCCC4 Therapeutics78.81%PBYIPuma Biotechnology61.29%SRZNSurrozen66.57%UPXIUpexi5.68%Insider OwnershipCompanyInsider OwnershipCCCCC4 Therapeutics5.60%PBYIPuma Biotechnology22.20%SRZNSurrozen31.74%UPXIUpexi9.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCCCCC4 Therapeutics150110.18 million104.01 millionOptionablePBYIPuma Biotechnology20050.90 million39.60 millionOptionableSRZNSurrozen8011.61 million7.84 millionNot OptionableUPXIUpexi13070.26 million60.89 millionOptionableUPXI, PBYI, SRZN, and CCCC HeadlinesRecent News About These CompaniesUpexi, Inc. Earnings Call Highlights Crypto-Fueled VolatilityMay 13 at 9:11 PM | tipranks.comUpexi Net Loss Balloons to $109 Million on Solana Treasury MarkdownMay 13 at 9:47 AM | finance.yahoo.comUpexi Q3 Earnings Call HighlightsMay 12 at 11:06 PM | marketbeat.comUpexi Reports Fiscal Third Quarter 2026 Financial ResultsMay 12 at 4:30 PM | globenewswire.comUpexi Q3 2026 earnings previewMay 11, 2026 | msn.comUpexi (NASDAQ:UPXI) Rating Increased to Sell at Wall Street ZenMay 10, 2026 | americanbankingnews.comUpexi (NASDAQ:UPXI) Raised to "Sell" at Wall Street ZenMay 10, 2026 | marketbeat.comUpexi to Present at the LD Micro Invitational XVI Conference on May 17-19May 7, 2026 | globenewswire.comUpexi (UPXI) Expected to Announce Quarterly Earnings on ThursdayMay 7, 2026 | marketbeat.comUpexi Provides Periodic Update to its Share Repurchase ProgramMay 6, 2026 | globenewswire.comUpexi to Host Third Quarter 2026 Earnings Call on May 12th at 5:30 p.m. ETMay 5, 2026 | globenewswire.comUpexi (NASDAQ:UPXI) Stock Rating Lowered by Wall Street ZenMay 2, 2026 | marketbeat.comUpexi to Participate in the Scottsdale Capital Event on April 10-12March 31, 2026 | globenewswire.comUpexi to Participate in Upcoming March Investor ConferencesMarch 3, 2026 | globenewswire.comUpexi Earnings Call: Growth Surges, Losses MountFebruary 15, 2026 | tipranks.comInsiders' US$4.22m Investments In Red Following Upexi's US$18m Dip In Market ValueFebruary 14, 2026 | finance.yahoo.comUpexi Inc (UPXI) Q2 2026 Earnings Call Highlights: Revenue Soars Amid Digital Asset ChallengesFebruary 13, 2026 | uk.finance.yahoo.comUpexi Inc (UPXI) Q2 2026 Earnings Call Highlights: Revenue Soars Amid Digital Asset ChallengesFebruary 13, 2026 | uk.finance.yahoo.comUpexi, Inc. (NASDAQ: UPXI) Q2 2026 earnings call transcriptFebruary 11, 2026 | msn.comUpexi (UPXI) Q2 2026 Earnings Call TranscriptFebruary 11, 2026 | finance.yahoo.comUpexi targets yield growth and capital market innovation amid Solana-driven volatilityFebruary 10, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeUPXI, PBYI, SRZN, and CCCC Company DescriptionsC4 Therapeutics NASDAQ:CCCC$3.63 -0.05 (-1.36%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$3.59 -0.04 (-1.10%) As of 07:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Puma Biotechnology NASDAQ:PBYI$7.19 +0.02 (+0.28%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$7.19 +0.00 (+0.03%) As of 07:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.Surrozen NASDAQ:SRZN$29.87 -0.27 (-0.90%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$29.19 -0.68 (-2.26%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.Upexi NASDAQ:UPXI$1.52 +0.13 (+9.35%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$1.47 -0.05 (-3.29%) As of 07:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies 2 Ways to Play the Big Pharma Patent Cliff Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
